Ascentage Pharma Group International (AAPG) Operating Leases (2022 - 2025)

Ascentage Pharma Group International (AAPG) has reported Operating Leases for 4 consecutive years, with $3.1 million the latest figure, recorded in Q4 2025.

• Quarterly Operating Leases fell 25.64% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 25.64% YoY) and the FY2025 annual result came in at $3.2 million, down 26.58% from the prior year.
• Operating Leases slipped to $3.1 million in Q4 2025 per AAPG's latest filing, from $4.2 million in the prior quarter.
• Over the last five years, Operating Leases for AAPG reached as high as $4.2 million in Q4 2024 and fell as low as $2.4 million in Q4 2022.
• A 4-year average of $3.2 million and a median of $3.1 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases soared 33.61% — and 2025, when it retreated 25.64%.
• Year by year, Operating Leases stood at $2.4 million in 2022, then soared by 30.09% to $3.2 million in 2023, then soared by 33.61% to $4.2 million in 2024, then fell by 25.64% to $3.1 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $3.1 million, $4.2 million, and $3.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.